Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €1.03 EUR
Change Today +0.01 / 0.98%
Volume 73.8K
ALNEV On Other Exchanges
EN Paris
As of 11:35 AM 05/5/15 All times are local (Market data is delayed by at least 15 minutes).

neovacs (ALNEV) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/16/14 - €4.04
52 Week Low
03/27/15 - €0.93
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for NEOVACS (ALNEV)

Related News

No related news articles were found.

neovacs (ALNEV) Related Businessweek News

No Related Businessweek News Found

neovacs (ALNEV) Details

Neovacs S.A., a biotechnology company, focuses on active immunotherapy for autoimmune and inflammatory diseases in France. The company’s product pipeline comprises tumor necrosis factor kinoid for the treatment of rheumatoid arthritis and Crohn’s diseases; interferon a-kinoid to treat lupus; and vascular endothelial growth factor kinoid for the treatment of macular degeneration and cancer. Neovacs S.A. is based in Paris, France.

neovacs (ALNEV) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: €34.9K
Compensation as of Fiscal Year 2013.

neovacs (ALNEV) Key Developments

Stellar Biotechnologies Enters into Expanded Supply Agreement with Neovacs

Stellar Biotechnologies, Inc. and Neovacs S.A. have entered into an expanded supply agreement, under which Stellar will supply its Keyhole Limpet Hemocyanin, or KLH, for Neovacs's proprietary Kinoid immunotherapy technology. The new agreement extends and expands the supply contracts previously in place between the Companies, in order to ensure the continued supply of Stellar KLH to Neovacs during its Kinoid clinical trials and to support the expected commercial roll-out of Neovacs' lead product candidate IFNalpha-Kinoid, an immunotherapy being developed for the treatment of systemic lupus erythematosus ("lupus").

Neovacs S.A. Presents at ChinaBio Partnering Forum 2015, Apr-15-2015 02:30 PM

Neovacs S.A. Presents at ChinaBio Partnering Forum 2015, Apr-15-2015 02:30 PM. Venue: Kerry Hotel, Pudong, Shanghai, China.

Neovacs Strengthens North American Presence with Formation of U.S. Subsidiary

NEOVACS announced the establishment of its wholly-owned U.S. subsidiary, Neovacs Inc. The creation of this U.S. subsidiary marks an important strategic step for Neovacs, as the company extends its clinical initiatives for lead product candidate, IFNa-Kinoid, beyond the EU to the U.S. market. The establishment of this subsidiary follows the formation of a U.S. Scientific Advisory Board in October 2013.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALNEV:FP €1.03 EUR +0.01

ALNEV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ALNEV.
View Industry Companies

Industry Analysis


Industry Average

Valuation ALNEV Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEOVACS, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at